da Fonseca D P, Joosten D, van der Zee R, Jue D L, Singh M, Vordermeier H M, Snippe H, Verheul A F
Eijkman-Winkler Institute for Microbiology, Infectious Diseases, and Inflammation, Section Vaccines, Academic Hospital Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
Infect Immun. 1998 Jul;66(7):3190-7. doi: 10.1128/IAI.66.7.3190-3197.1998.
Induction of cytotoxic T lymphocytes (CTLs) by vaccination has been shown to protect against bacterial, viral, and tumoral challenge. The aim of this study was to identify CTL epitopes on the 38-kDa lipoglycoprotein from Mycobacterium tuberculosis. The identification of these CTL epitopes was based on synthesizing peptides designed from the 38-kDa lipoglycoprotein, with known major histocompatibility complex class I (MHC-I) binding motifs (H-2Db), and studying their ability to up-regulate and stabilize MHC-I molecules on the mouse lymphoma cell line RMA-S. To improve the capacity of the identified peptides to induce CTL responses in mice, palmitic acid with a cysteine-serine-serine spacer amino acid sequence was attached to the amino terminus of the peptide. Two of five peptides with H-2Db binding motifs and their corresponding lipopeptides up-regulated and stabilized the H-2Db molecules on RMA-S cells. Both lipopeptides, in combination with incomplete Freund's adjuvant, induced CTL responses in C57BL/6 (H-2(b)) mice. Moreover, the lipopeptide induced stronger CTL responses than the peptide. The capacity of the various lipopeptides to induce CTL displayed a good relationship with the ability of the (lipo)peptide to up-regulate and to stabilize H-2Db molecules. The capacity of the peptides and lipopeptides to up-regulate and stabilize MHC-I expression can therefore be used to predict their potential to function as a CTL epitope. The newly identified CTL epitopes and their lipid derivatives provide us with important information for future M. tuberculosis vaccine design.
通过疫苗接种诱导细胞毒性T淋巴细胞(CTL)已被证明可抵御细菌、病毒和肿瘤的攻击。本研究的目的是鉴定结核分枝杆菌38 kDa脂糖蛋白上的CTL表位。这些CTL表位的鉴定基于合成从38 kDa脂糖蛋白设计的肽段,这些肽段具有已知的主要组织相容性复合体I类(MHC-I)结合基序(H-2Db),并研究它们上调和稳定小鼠淋巴瘤细胞系RMA-S上MHC-I分子的能力。为了提高所鉴定肽段在小鼠中诱导CTL反应的能力,将具有半胱氨酸-丝氨酸-丝氨酸间隔氨基酸序列的棕榈酸连接到肽段的氨基末端。五个具有H-2Db结合基序的肽段中的两个及其相应的脂肽上调并稳定了RMA-S细胞上的H-2Db分子。两种脂肽与不完全弗氏佐剂联合使用,在C57BL/6(H-2(b))小鼠中诱导了CTL反应。此外,脂肽诱导的CTL反应比肽段更强。各种脂肽诱导CTL的能力与(脂)肽上调和稳定H-2Db分子的能力呈现良好的相关性。因此,肽段和脂肽上调和稳定MHC-I表达的能力可用于预测它们作为CTL表位发挥功能的潜力。新鉴定的CTL表位及其脂质衍生物为未来结核分枝杆菌疫苗设计提供了重要信息。